[1] Chiu DK,Yuen VW,Cheu JW,et al.Hepatocellular carcinoma cells up-regulate PVRL1,stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice[J].Gastroenterology2020,159(2):609-623. [2] Li XY,Das I,Lepletier A,et al.CD155 loss enhances tumor suppression via co-mbined host and tumor-intrinsic mechanisms[J].Clin Invest,2018,128(6):2613-2625. [3] Braun M,Aguilera AR,Sundarrajan A,et al.CD155 on tumor cells drives resistance to immunotherapy by inducing the degradation of the activating receptor CD226 in CD8+ T cells[J].Immunity,2020,53(4):805-823. [4] Josefsson SE,Huse K,Kolstad A,et al.T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling[J].Clin Cancer Res,2018,24(4):870-881. [5] Lozano E,Mena MP,Díaz T,et al.Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma[J].Clin Cancer Res,2020,26(17):4688-4698. [6] Yang ZZ,Kim HJ,Wu H,et al.TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma[J].Clin Cancer Res,2020,26(19):5217-5231. [7] Liu X,Li M,Wang X,et al.PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma[J].Cancer Immunol Immunother,2019,68(12):2041-2054. [8] Ostroumov D,Duong S,Wingerath J,et al.Transcriptome profiling identifies TIGIT as a marker of T-cell exhaustion in liver cancer[J].Hepatology,2021,73 (4):1399-1418. [9] Chiu DK,Yuen VW,Cheu JW,et al.Hepatocellular carcinoma cells up-regulate PVRL1,stabilizing PVR and inhibiting the cytotoxic T-cell response via TIGIT to mediate tumor resistance to PD1 inhibitors in mice[J].Gastroenterology,2020,159(2):609-623. [10] Ge Z,Zhou G,Campos Carrascosa L,et al.TIGIT and PD1 co-blockade restores ex vivo functions of human tumor-infiltrating CD8+ T cells in hepatocellular carcinoma[J].Cell Mol Gastroenterol Hepatol,2021,12(2):443-464. [11] Lozano E,Mena MP,Díaz T,et al.Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma[J].Clin Cancer Res,2020,26(17):4688-4698. [12] Fourcade J,Sun Z,Chauvin JM,et al.CD226 opposes TIGIT to disrupt tregs in melanoma[J].CI Insight,2018,3(14):121157. [13] Lepletier A,Madore J,O'Donnell JS,et al.Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma[J].Clin Cancer Res,2020,26(14):3671-3681. [14] Sanchez-Correa B,Valhondo I,Hassouneh F,et al.DNAM-1 and the TIGIT/PVRIG /TACTILE axis:novel immune checkpoints for natural killer cell-based cancer immunotherapy[J].Cancers (Basel),2019,11(6):877. [15] Josefsson SE,Beiske K,Blaker YN,et al.TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-hodgkin lymphoma[J].Cancer Immunol Res,2019,7(3):355-362. [16] Souza-Fonseca-Guimaraes F,Cursons J,Huntington ND.The emergence of natural killer cells as a major target in cancer immunotherapy[J].Trends Immunol,2019,40(2):142-158. [17] Kumagai S,Togashi Y,Kamada T,et al.The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies[J].Nat Immunol,2020,21(11):1346-1358. [18] Dixon KO,Schorer M,Nevin J,et al.Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity[J].Immunol,2018,200(8):3000-3007. [19] Reches A,Ophir Y,Stein N,et al.Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity[J].Immunother Cancer,2020,8 (1):266. [20] Lucca LE,Lerner BA,Park C,et al.Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS[J].Neurol Neuroimmunol Neuroinflamm,2020,7(3):712. [21] Torrejon DY,Abril-Rodriguez G,Champhekar AS,et al.Overcoming genetically based resistance mechanisms to PD-1 blockade[J].Cancer Discov,2020,10(8):1140-1157. [22] Chauvin JM,Ka M,Pagliano O,et al.IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-Cell dysfunction in melanoma[J].Clin Cancer Res,2020,26(20):5520-5533. [23] Maas RJ,Hoogstad-van Evert JS,Van der Meer JM,et al.TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer[J].Oncoimmunology,2020,9 (1):1843247. [24] Niu J,Maurice-Dror C,Lee DH,et al.First-in-human phase 1 study of the anti- TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors,including non-small-cell lung cancer☆[J].Ann Oncol,2022,33 (2):169-180. [25] Rodriguez-Abreu D,Johnson ML,Hussein MA,et al.Primary analysis of a randomized,double-blind,phase II study of the anti-TIGIT antibody tiragolumab (Tira) plus atezolizumab (Atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)[J].Clin Oncol,2020,38:9503.
2023, Vol. 29 
冀公网安备13080202000677号